search

Active clinical trials for "Neoplasms"

Results 3321-3330 of 64586

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the...

Pancreatic Cancer

This study is designed to explore the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as peri-operative treatment in locally advanced or borderline resectable pancreatic cancer.

Recruiting27 enrollment criteria

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First...

Acute Myeloid Leukemia

This clinical study evaluates the efficacy and safety of maintenance therapy with BCL-2 inhibitors in elderly patients with acute myeloid leukemia (AML) in first complete remission. This study involves the following content: BCL-2 inhibitors.

Recruiting21 enrollment criteria

A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer

Advanced Lung Cancer

In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.

Recruiting8 enrollment criteria

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory...

Relapsed/ Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Recruiting22 enrollment criteria

Prevention of Oral Mucositis in Head and Neck Cancer.

Oral Mucositis

Oral Mucositis (OM) consists in the painful inflammation and ulceration of the mucous membranes lining the digestive tract, lasting between 7 and 98 days; and starts as an acute inflammation of oral mucosa, tongue, and pharynx after RT exposure. Gel X spray is a product based on zinc gluconate. It could be helpful to achieve the prevention of Oral Mucositis and, in case of OM manifestation, the reduction of oral pain symptoms and to accelerate the healing process of oral mucositis ulcerations. The aim of this study is to demonstrate the efficacy of the treatment with Gel X to reduce the incidence of oral mucositis, in comparison with Sodium Bicarbonate.

Recruiting6 enrollment criteria

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial...

Metastatic Malignancy

To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.

Recruiting68 enrollment criteria

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC

Esophageal Squamous Cell CarcinomaTislelizumab1 more

This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.

Recruiting28 enrollment criteria

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab...

Relapsed or Refractory Multiple Myeloma

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

Recruiting9 enrollment criteria

Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin,...

Diffuse Large B-Cell LymphomaGrade 3b Follicular Lymphoma1 more

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard chemotherapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found on B-cells (a type of white blood cell) and some types of cancer cells. Rituximab binds to a protein called CD20, which is also found on B-cells and some cancer cells. These monoclonal antibodies may help the immune system kill cancer cells. Immunotherapy with other monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as CHOP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TRR in combination with CHOP may kill more cancer cells.

Recruiting40 enrollment criteria

A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of...

Glioblastoma

This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery. Part 2 is open to people who already had such a brain surgery. This study tests a medicine called BI 907828. BI 907828 is a so-called Murine double minute 2 (MDM2) inhibitor that is being developed to treat cancer. The purpose of Part 1 of the study is to find out how BI 907828 is taken up in the tumor. Participants take a single dose of BI 907828 as a tablet before the brain surgery. Part 1 of the study takes about 1 month. During this time, participants have their brain tumor removed by surgery and visit the study site about 8 times. The purpose of Part 2 is to find the highest dose of BI 907828 that the participants can tolerate in combination with standard radiation therapy. During the first 6 weeks, participants get standard radiation therapy. In addition, they take a dose of BI 907828 once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. During the entire study, doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting17 enrollment criteria
1...332333334...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs